Rallybio Corp. (RLYB)
16.80
-0.03
(-0.18%)
USD |
NASDAQ |
Aug 24, 16:00
16.80
0.00 (0.00%)
After-Hours: 20:00
Rallybio Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.0031 |
| December 31, 2025 | 0.003 |
| September 30, 2025 | 0.0031 |
| June 30, 2025 | 0.0013 |
| March 31, 2025 | 0.0021 |
| December 31, 2024 | 0.0025 |
| September 30, 2024 | 0.0032 |
| June 30, 2024 | 0.0035 |
| March 31, 2024 | 0.0038 |
| December 31, 2023 | 0.0037 |
| September 30, 2023 | 0.0035 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.0034 |
| March 31, 2023 | 0.0033 |
| December 31, 2022 | 0.0033 |
| September 30, 2022 | 0.0045 |
| June 30, 2022 | 0.0042 |
| March 31, 2022 | 0.0041 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Q32 Bio, Inc. | 0.05 |
| Beam Therapeutics, Inc. | 0.2317 |
| C4 Therapeutics, Inc. | 0.2299 |
| Cullinan Therapeutics, Inc. | 0.0064 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 98.06M |
| Total Liabilities (Quarterly) | 3.567M |
| Shareholders Equity (Quarterly) | 94.50M |
| Current Ratio | 27.26 |
| Net Debt Paydown Yield | 0.03% |